Xultophy approved for renal impairment
Richard Thomas,
1 Min
Xultophy approved for renal impairment
Richard Thomas,
1 Min
In Clinical
Follow this topic
Bookmark
Record learning outcomes
The European Commission recently approved Xultophy (insulin degludec plus liraglutide) for adults with type 2 diabetes and moderate renal impairment (creatinine clearance 30-59ml/min). Up to 40 per cent of people with type 2 diabetes develop some degree of renal impairment.
Record my learning outcomes
Save for later
Share:
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.